22996-19-6Relevant articles and documents
Design, Synthesis, and Characterization of Novel Small Molecules as Broad Range Antischistosomal Agents
Rugel, Anastasia,Tarpley, Reid S.,Lopez, Ambrosio,Menard, Travis,Guzman, Meghan A.,Taylor, Alexander B.,Cao, Xiaohang,Kovalskyy, Dmytro,Chevalier, Frédéric D.,Anderson, Timothy J. C.,Hart, P. John,Loverde, Philip T.,McHardy, Stanton F.
, p. 967 - 973 (2018)
Schistosomiasis is a major human parasitic disease afflicting more than 250 million people, historically treated with chemotherapies praziquantel or oxamniquine. Since oxamniquine is species-specific, killing Schistosoma mansoni but not other schistosome species (S. haematobium or S. japonicum) and evidence for drug resistant strains is growing, research efforts have focused on identifying novel approaches. Guided by data from X-ray crystallographic studies and Schistosoma worm killing assays on oxamniquine, our structure-based drug design approach produced a robust structure-activity relationship (SAR) program that identified several new lead compounds with effective worm killing. These studies culminated in the discovery of compound 12a, which demonstrated broad-species activity in killing S. mansoni (75%), S. haematobium (40%), and S. japonicum (83%).
Structure-Based Drug Design of Potent Pyrazole Derivatives against Rhinovirus Replication
Da Costa, Laurène,Scheers, Els,Coluccia, Antonio,Casulli, Adriano,Roche, Manon,Di Giorgio, Carole,Neyts, Johan,Terme, Thierry,Cirilli, Roberto,La Regina, Giuseppe,Silvestri, Romano,Mirabelli, Carmen,Vanelle, Patrice
, p. 8402 - 8416 (2018/09/18)
Rhinoviruses (RVs) have been linked to exacerbations of many pulmonary diseases, thus increasing morbidity and/or mortality in subjects at risk. Unfortunately, the wide variety of RV genotypes constitutes a major hindrance for the development of Rhinovirus replication inhibitors. In the current investigation, we have developed a novel series of pyrazole derivatives that potently inhibit the Rhinovirus replication. Compounds 10e and 10h behave as early stage inhibitors of Rhinovirus infection with a broad-spectrum activity against RV-A and RV-B species (EC50 0.1 μM). We also evaluate the dynamics of the emerging resistance of these promising compounds and their in vitro genotoxicity. Molecular docking experiments shed light on the pharmacophoric elements interacting with residues of the drug-binding pocket.
Debundling, selection and release of SWNTs using fluorene-based photocleavable polymers
Lemasson, Fabien,Tittmann, Jana,Hennrich, Frank,Stuerzl, Ninette,Malik, Sharali,Kappes, Manfred M.,Mayor, Marcel
supporting information; experimental part, p. 7428 - 7430 (2011/08/08)
Photocleavable polymers based on 9,9-dialkylfluorene backbone and o-nitrobenzylether were designed and synthesized to obtain stable (n,m) enriched suspensions of semiconducting SWNTs in toluene. Photoirradiation of the suspensions triggered the precipitat
